NASDAQ:CRXT - Clarus Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.43
  • Forecasted Upside: 136.28 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$5.26
▼ -0.1 (-1.87%)

This chart shows the closing price for CRXT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Clarus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRXT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRXT

Analyst Price Target is $12.43
▲ +136.28% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Clarus Therapeutics in the last 3 months. The average price target is $12.43, with a high forecast of $20.00 and a low forecast of $10.00. The average price target represents a 136.28% upside from the last price of $5.26.

This chart shows the closing price for CRXT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Clarus Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/18/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2021Truist FinancialInitiated CoverageBuy$10.00High
10/13/2021TruistInitiated CoverageBuy ➝ Buy$10.00High
10/13/2021Truist SecuritiesInitiated CoverageBuy$10.00High
10/6/2021Needham & Company LLCInitiated CoverageBuy$12.00High
9/29/2021Maxim GroupInitiated CoverageBuy$13.00High
9/20/2021OppenheimerInitiated CoverageOutperform$12.00High
9/20/2021Cantor FitzgeraldInitiated CoverageOverweight$20.00High
(Data available from 10/18/2016 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/18/2021
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/18/2021

Current Sentiment

  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Clarus Therapeutics logo
Clarus Therapeutics Inc. is a specialty pharmaceutical company which provide solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women. The Company's commercial product includes JATENZO(R). Clarus Therapeutics Inc., formerly known as Blue Water Acquisition Corp., is based in NORTHBROOK, Ill.
Read More

Today's Range

Now: $5.26
Low: $5.26
High: $5.26

50 Day Range

MA: N/A

52 Week Range

Now: $5.26
Low: $3.43
High: $31.24

Volume

200 shs

Average Volume

590,039 shs

Market Capitalization

$114.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Clarus Therapeutics?

The following Wall Street analysts have issued stock ratings on Clarus Therapeutics in the last year: Cantor Fitzgerald, Maxim Group, Needham & Company LLC, Oppenheimer Holdings Inc., Truist, Truist Financial Co., and Truist Securities.
View the latest analyst ratings for CRXT.

What is the current price target for Clarus Therapeutics?

7 Wall Street analysts have set twelve-month price targets for Clarus Therapeutics in the last year. Their average twelve-month price target is $12.43, suggesting a possible upside of 136.3%. Cantor Fitzgerald has the highest price target set, predicting CRXT will reach $20.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $10.00 for Clarus Therapeutics in the next year.
View the latest price targets for CRXT.

What is the current consensus analyst rating for Clarus Therapeutics?

Clarus Therapeutics currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRXT will outperform the market and that investors should add to their positions of Clarus Therapeutics.
View the latest ratings for CRXT.

How do I contact Clarus Therapeutics' investor relations team?

Clarus Therapeutics' physical mailing address is 15 E. PUTNAM AVENUE SUITE 363, GREENWICH CT, 06830. The company's listed phone number is 646-303-0737.